Ocular Therapeutix announced topline results from its Phase 3 clinical trial to evaluate the safety and efficacy of DEXTENZA for the treatment of ocular itching associated with allergic conjunctivitis (AC).
Novartis has unveiled plans to begin a phase III clinical study to evaluate canakinumab, an interleukin (IL)-1β blocker, in patients with COVID-19 pneumonia.
Moderna, a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) for the company’s mRNA vaccine candidate (mRNA-1273) against the novel coronavirus (SARS-CoV-2) to evaluate mRNA-1273 in Phase 2 and late-stage studies if supported by safety data from the Phase 1 study led by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
Verastem announced results from the ongoing investigator-initiated Phase 1 clinical study investigating VS-6766, its RAF/MEK inhibitor, in combination with defactinib, its FAK inhibitor, in patients with KRAS mutant advanced solid tumors.
AstraZeneca and Merck said that their co-developed cancer drug Lynparza (olaparib) demonstrated overall survival (OS) benefit in a phase 3 trial in a certain patient population with prostate cancer.
AstraZeneca, along with the Saint Luke’s Mid America Heart Institute, has commenced a phase III DARE-19 study with Farxiga (dapagliflozin) in COVID-19 patients.
Emergex Vaccines Holding, a biotechnology company developing CD8+ priming set-point vaccines to prevent serious infectious diseases, today announced that it has entered into an agreement with the George Mason University, based in Virginia, in the United States.
Hope Biosciences announces FDA approval on their third clinical trial for COVID-19.
Bristol-Myers Squibb (BMS) said that the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) met the primary endpoint of a phase 3 trial in previously untreated malignant pleural mesothelioma (MPM).
Alexion Pharmaceuticals announced plans to initiate a global Phase 3 study to investigate ULTOMIRIS (ravulizumab-cwvz) in a subset of adults with COVID-19 – those who are hospitalized with severe pneumonia or acute respiratory distress syndrome (ARDS).
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.